ScoreWhy is Jagsonpal Pharmaceuticals Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0 times
2
With a growth in Net Profit of 179.14%, the company declared Very Positive results in Dec 24
- The company has declared positive results for the last 3 consecutive quarters
- PAT(9M) At Rs 32.07 cr has Grown at 69.60%
- NET SALES(9M) At Rs 210.16 cr has Grown at 27.21%
3
Stock is technically in a Mildly Bullish range
- The stocks MACD and KST technical factors are also Bullish
4
With ROE of 18.1, it has a Very Expensive valuation with a 6.8 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 79.52%, its profits have risen by 45.3% ; the PEG ratio of the company is 0.9
5
Despite the size of the company, domestic mutual funds hold only 0% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
6
Market Beating performance in long term as well as near term
- Along with generating 79.52% returns in the last 1 year, the stock has outperformed BSE 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Jagsonpal Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Drugs should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Jagsonpal Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Jagsonpal Pharma
80.53%
1.24
63.89%
SENSEX
0.45%
0.03
14.48%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.66%
EBIT Growth (5y)
32.18%
EBIT to Interest (avg)
26.48
Debt to EBITDA (avg)
0.39
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.37
Tax Ratio
20.34%
Dividend Payout Ratio
58.85%
Pledged Shares
0
Institutional Holding
2.10%
ROCE (avg)
30.44%
ROE (avg)
14.53%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
38
Industry P/E
33
Price to Book Value
6.80
EV to EBIT
32.78
EV to EBITDA
28.26
EV to Capital Employed
9.86
EV to Sales
5.02
PEG Ratio
0.86
Dividend Yield
0.99%
ROCE (Latest)
21.97%
ROE (Latest)
18.07%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend21What is working for the Company
PAT(9M)
At Rs 32.07 cr has Grown at 69.60%
NET SALES(9M)
At Rs 210.16 cr has Grown at 27.21%
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Jagsonpal Pharma
Profit After Tax (PAT) - Quarterly
At Rs 12.81 cr has Grown at 91.5% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 6.69 CrMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
At Rs 74.03 cr has Grown at 30.5% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 56.71 CrMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 12.81 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
